Surface-enhanced Raman Spectroscopy Immunoassay for Detection of Category A Patho

用于检测 A 类病理的表面增强拉曼光谱免疫分析

• 批准号: 8695035
• 负责人: Marc D Porter
• 金额: $ 91.82万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-06-01 至 2019-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8695035
• 关键词: Anthrax disease; Antigens; Applications Grants; Arts; Bacillus anthracis; Binding; Biological; Biological Assay; Biological Warfare; Botulinum Toxins; Botulism; Categories; Certification; Characteristics; Chemicals; Chemistry; Clinical; Communication; Containment; Country; Data Analyses; Detection; Development; Diagnostic; Diagnostic Sensitivity; Diagnostic Specificity; Diagnostic tests; Disease; Engineering; Equipment; Event; FDA approved; Fiber Optics; Goals; Gold; Human Resources; Immunoassay; Immunological Diagnosis; In Vitro; Label; Laboratories; Laboratory Procedures; Laboratory Research; Lasers; Legal patent; Life; Measurement; Medical Device; Methods; Monoclonal Antibodies; National Institute of Allergy and Infectious Disease; Pathology; Pathway interactions; Performance; Phase; Plague; Preparation; Probability; Process; Public Health; Raman Spectrum Analysis; Reading; Recombinants; Recording of previous events; Reporter; Resource Development; Safety; Sampling; Scientist; Series; Serum; Serum Markers; Signal Transduction; Source; Specificity; Speed; Staging; Surface; System; Technology; Testing; Training; Universities; Utah; Validation; Virus; Wireless Technology; Work; Yersinia pestis; active method; base; biodefense; biosafety level 3 facility; botulinum; combat; cost; cost effectiveness; design; experience; improved; innovation; instrument; instrumentation; medical schools; microorganism toxin; monolayer; nanoparticle; particle; pathogen; pathogen exposure; performance tests; portability; prototype; public health relevance; rapid detection; rapid technique; surfactant; technique development; therapeutic vaccine; tool; weapons of mass destruction

DESCRIPTION (provided by applicant): Recent events have placed the need for the development of reliable techniques for the rapid, low-level detection of NIAID Category A Priority Pathogens (Category A Pathogens) at an even more critical level. This project will develop deployable, nanoparticle-based, surface enhanced Raman scattering (SERS) diagnostic tests to fill this need. In so doing, this project will focus on serum markers for three well characterized Category A Pathogens (i.e., Bacillus anthracis, Clostridium botulinum toxin, and Yersinia pestis) in devising and performance-validating a multiplexed diagnostic panel based on the ultrasensitive detection of extrinsic Raman labels (ERLs) selectively bound to captured active pathogen antigens. ERLs will use unique Raman reporter molecules (RRMs) and monoclonal antibodies (mAbs) to selectively bind to captured antigens and to generate a markedly enhanced signal for ultra-low-level detection. Concurrently, we will also design and manufacture prototypes of a lightweight integrated, closed, sample-to-answer platform capable of reading the characteristic SERS spectrum from the ERLs when excited by a new diode laser. The platform will be field-deployable, have a desktop printer-size footprint, and have a readout of ~2 min for a 96-well microplate. As assays for the deactivated pathogens are validated in the laboratory the procedures will be transferred into a BSL-3 facility where methods for the active Category A Pathogen markers will be validated. When the prototypic Raman instruments and panel kits are available, they will be beta-tested and performance validated in the research laboratory (with deactivated markers) and in the BSL-3 facility (with active markers) at the U.S. Army's Dugway Proving Ground (DPG). This project represents a partnership between scientists and engineers at the University of Utah, B&W Tek, Inc. (a global leader in Raman spectroscopy and related automated instrumentation), and DPG.

描述（由申请人提供）：最近的事件使得对NIAID A类优先病原体（A类病原体）的快速、低水平检测的可靠技术的开发需求处于更加关键的水平。该项目将开发可部署的、基于纳米粒子的表面增强拉曼散射（SERS）诊断测试来满足这一需求。在此过程中，本项目将重点研究三种血清标记物